Effectiveness and Safety of Mirikizumab after switching from Ustekinumab in patients with moderate to severe Crohn's disease: results from a long-term extension study

被引：0

作者：

D'Haens, G. ^{[1
]}

Laharie, D. ^{[2
,3
]}

Dulai, P. S. ^{[4
]}

Seibold, F. ^{[5
]}

Siegmund, B. ^{[6
]}

Abraham, B. ^{[7
,8
,9
]}

Malter, L. ^{[10
]}

Protic, M. ^{[11
]}

Morris, N. ^{[11
]}

Hozak, R. R. ^{[11
]}

Moses, R. E. ^{[11
]}

Lopes, M. Ugolini ^{[11
]}

Durand, F. ^{[11
]}

Yu, G. ^{[11
]}

Vermeire, S. ^{[12
]}

机构：

[1] Amsterdam Univ Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

[2] Hop Haut Leveque, CHU Bordeaux, Serv Hepatogastroenterol, Bordeaux, France

[3] Univ Hosp Bordeaux, Digest Oncol Dept, Bordeaux, France

[4] Univ Calif San Diego, Div Gastroenterol, Los Angeles, CA 90089 USA

[5] Crohn Colitis Zentrum Intesto, Lindenhofspital, Bern, Switzerland

[6] Charite, Med Dept, Div Gastroenterol Infectiol & Rheumatol, Berlin, Germany

[7] Houston Methodist Hosp, Houston Methodist Gastroenterol Associates, Houston, TX USA

[8] Houston Methodist Acad Inst, Dept Med, Houston, TX USA

[9] Weill Cornell Med Coll, Dept Med, New York, NY USA

[10] NYU Langone Hlth, Div Gastroenterol, Dept Med, New York, NY USA

[11] Eli Lilly & Co, Lilly Immunol, Indianapolis, IN USA

[12] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, KU Leuven, Dept Chron Dis & Metab, Leuven, Belgium

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.0085

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP046

引用

页码：i168 / i170

页数：3

共 50 条

[1] Efficacy and Safety of Long-Term Mirikizumab Treatment in Patients With Moderate to Severe Crohn's Disease
Sands, Bruce E.
D'Haens, Geert R.
Hisamatsu, Tadakazu
Jairath, Vipul
Barnes, Edward
Pellanda, Paola
Hozak, Rebecca
Lin, Zhantao
Yu, Guanglei
Protic, Marijana
Owen, Charles C.
Fischer, Monika
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1040 - S1041
[2] Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn's disease: Results from the phase 3 VIVID 1 study
Jairath, V.
Sands, B. E.
Bossuyt, P.
Farraye, F.
Ferrante, M.
Hisamatsu, T.
Kaser, A.
Kierkus, J.
Laharie, D.
Reinisch, W.
Siegmund, B.
Bragg, S. M.
Hon, E.
Lin, Z.
Lopes, M. Ugolini
Morris, N.
Protic, M.
Danese, S.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I62 - I64
[3] Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study
Mocci, Giammarco
Tursi, Antonio
Scaldaferri, Franco
Napolitano, Daniele
Pugliese, Daniela
Capobianco, Ivan
Bartocci, Bianca
Blasi, Valentina
Savarino, Edoardo V.
Maniero, Daria
Redavid, Carlo
Lorenzon, Greta
Cuomo, Antonio
Donnarumma, Laura
Gravina, Antonietta Gerarda
Pellegrino, Raffaele
Bodini, Giorgia
Pasta, Andrea
Marzo, Manuela
Serio, Mariaelena
Scarcelli, Antonella
Rodino, Stefano
Sebkova, Ladislava
Maconi, Giovanni
Cataletti, Giovanni
Luppino, Ileana
Checchin, Davide
Ferronato, Antonio
Gaiani, Federica
Kayali, Stefano
Felice, Carla
Pranzo, Giuseppe
Catarella, Domenico
D'Agostino, Dario
Di Bartolo, Elisabetta
Lombardi, Giovanni
Patturelli, Marta
Bendia, Emanuele
Bolognini, Laura
Balducci, Daniele
Quatraccioni, Claudia
Martini, Francesco
Mucherino, Caterina
D'Antonio, Elvira
Montesano, Laura
Vespere, Giuliana
Sedda, Silvia
D'Onofrio, Vittorio
De Luca, Leonardo
Spagnuolo, Rocco
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (23)
[4] EFFICACY OF MIRIKIZUMAB IN COMPARISON TO USTEKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VIVID 1 STUDY
D'Haens, Geert
Danese, Silvio
Sands, Bruce E.
Bossuyt, Peter
Farraye, Francis A.
Ferrante, Marc
Hisamatsu, Tadakazu
Kaser, Arthur
Kierkus, Jaroslaw
Laharie, David
Reinisch, Walter
Siegmund, Britta
Bragg, Sonja M.
Hon, Emily
Lin, Zhantao
Lopes, Michelle
Morris, Nathan
Protic, Marijana
Jairath, Vipul
GASTROENTEROLOGY, 2024, 166 (05) : S238 - S239
[5] USTEKINUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE UNISTAR STUDY LONG-TERM EXTENSION
Rosh, Joel R.
Turner, Dan
Cohen, Stanley A.
Griffiths, Anne M.
Hyams, Jeffrey S.
Kierkus, Jaroslaw
Adedokun, Omoniyi J.
Strauss, Richard
Kim, Lilianne
Volger, Sheri
GASTROENTEROLOGY, 2023, 164 (06) : S1185 - S1185
[6] Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extension
Turner, D.
Rosh, J. R.
Cohen, S. A.
Griffiths, A.
Hyams, J. S.
Kierkus, J.
Adedokun, O. J.
Strauss, R.
Kim, L.
Volger, S.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 802 - 803
[7] Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study
Thomas, Pepijn W. A.
van Caem, Mark
West, Rachel L.
Russel, Maurice G. V. M.
Jansen, Jeroen M.
Romkens, Tessa E. H.
Hoentjen, Frank
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 35 (03) : 261 - 269
[8] LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH TWO YEARS
Sandborn, William J.
Rutgeerts, Paul
Gasink, Christopher
Jacobstein, Douglas
Gao, Long-Long
Johanns, Jewel
Sands, Bruce E.
Hanauer, Stephen B.
Targan, Stephan R.
Ghosh, Subrata
de Villiers, Willem J.
Colombel, Jean Frederic
Feagan, Brian G.
GASTROENTEROLOGY, 2017, 152 (05) : S585 - S585
[9] Long-term efficacy and safety of mirikizumab treatment for Crohn's Disease: Results from the VIVID-2 open-label extension study
Vermeire, S.
Sands, B. E.
D'Haens, G.
Hisamatsu, T.
Kelly, C. R.
Lu, N.
Morris, N.
Moses, R.
Durand, F.
Protic, M.
Hozak, R. R.
Lopes, M. U.
Regueiro, M.
Laharie, D.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i87 - i89
[10] Long term efficacy and safety of Ustekinumab for Crohn's disease: results from IM-UNITI long-term extension through 2 years
Sandborn, W.
Rutgeerts, P.
Gasink, C.
Jacobstein, D.
Gao, L. -L.
Johanns, J.
Sands, B.
Hanauer, S. B.
Targan, S.
Ghosh, S.
de Villiers, W. J. S.
Colombel, J. -F.
Feagan, B. G.
JOURNAL OF CROHNS & COLITIS, 2017, 11 : S6 - S6

← 1 2 3 4 5 →